According to the department, the Hepcludex injection is the first treatment for hepatitis delta virus (HDV) in adults lacking cirrhosis or with compensated cirrhosis. “Today’s approval fills a ...
A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the dangerous liver ...
Most people recover from the infection, but it poses great risks for those who don’t. A new drug may cure 1 in 5 of these ...
Citi is holding back from recommending GSK PLC (LSE:GSK, NYSE:GSK) shares despite a significant clinical breakthrough in hepatitis B treatment, arguing that unanswered commercial questions mean any ...
A groundbreaking drug, bepirovirsen, has shown promise in achieving a functional cure for hepatitis B, with 20% of patients ...
The sneaky virus poses serious health threats if it goes on to become a chronic disease. Clinical trial results suggest a new ...
An experimental hepatitis B drug shows potential for a functional cure, allowing some patients to stop treatment without ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. An experimental medicine helped ...
Bepirovirsen achieved functional cures in about 1 in 5 patients in global trials; FDA review is set for Oct. 26, 2026.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis ...
1d
GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript
Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment May 28, 2026 10:00 AM EDTCompany ParticipantsConstantin Fest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results